PROCLEIX West Nile virus assay based on transcription-mediated amplification.
Tools
Tools
Ziermann, Rainer and Sanchez-Guerrero, Sergio Arturo (2008) PROCLEIX West Nile virus assay based on transcription-mediated amplification. Expert Review of Molecular Diagnostics, 8 (3). pp. 239-245. ISSN 1744-8352
Abstract
The PROCLEIX West Nile virus (WNV) assay is based on transcription-mediated amplification and is the most sensitive nucleic acid test commercially available today for blood screening. Since 2003, in the USA, the assay has been used for year-round screening of blood donations in minipools of 16 and in an individual-donation testing format, when appropriate triggering guidelines for such switch become effective. The test can be run on the semiautomated PROCLEIX modular platform or the fully-automated PROCLEIX TIGRIS System. This assay and the corresponding platforms have been developed and are manufactured by San Diego-based Gen-Probe, Inc., while they are marketed and distributed by Chiron, a Novartis business. This review covers some of the epidemiological and virological aspects of WNV, as well as clinical questions and technological assessment of the transcription-mediated amplification and alternative technologies used in WNV blood screening.
| Item Type: | Article |
|---|---|
| Related URLs: | |
| Additional Information: | author can archive post-print (ie final draft post-refereeing); 12 months for institutional or subject based servers |
| Related URLs: | |
| Date Deposited: | 14 Dec 2009 13:52 |
| Last Modified: | 14 Dec 2009 13:52 |
| URI: | https://oak.novartis.com/id/eprint/831 |